HIS companies should not be underestimated

Article

HIS companies should not be underestimatedIt should be no surprise that healthcare information system vendors are turning their attention to the PACS market. PACS is a high-priced technology that, despite years of being on the cusp of success,

HIS companies should not be underestimated

It should be no surprise that healthcare information system vendors are turning their attention to the PACS market. PACS is a high-priced technology that, despite years of being on the cusp of success, remains at a very preliminary level of market implementation, especially in large-scale applications.

Additionally, the technological hurdles that have historically kept IS companies out of the market have largely been removed. Standards like DICOM and HL-7 have eased some of the complex integration requirements, while the exponential increase in PC processing power has enabled development of low-cost workstations and other PACS technology.

Can HIS vendors succeed? Market conditions would seem to favor them. Hospitals continue to consolidate and deal with cost pressures, and information systems that can provide enterprise-wide access to both medical images and patient information could strike a chord in IS departments.

Meanwhile, PACS vendors need to prepare for this eventuality, if they haven't already. By continually working to maintain the highest level of conformance to standards, PACS companies will find themselves still in a strong competitive position even when PACS becomes integrated into an enterprise-wide information system. Thanks to their long experience with the demanding technology, PACS vendors also hold a keen sense of radiology work flow. This is an important lesson that IS vendors must comprehend, because PACS technology that does not pass muster in the radiology department is doomed to failure.

-Erik L. Ridley, Editor

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.